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Abstract 
Background: Low molecular weight protein tyrosine phosphatase (LMW-PTP) is overexpressed in different cancer 
types and its expression is related to more aggressive disease, reduced survival rate and drug resistance. Morin is a 
natural polyphenol which negatively modulates, among others, the activity of LMW-PTP, leading to the potentiation 
of the effects of different antitumoral drugs, representing a potential beneficial treatment against cancer.
Methods: LMW-PTP levels were measured by immunoblot analysis both in CLL cells from patients and in chronic 
lymphocytic leukemia (CLL)-derived Mec-1 cells. Cell viability was assessed in Mec-1 cells treated with morin alone or 
in combination with either fludarabine or ibrutinib or following siRNA-mediated LMW-PTP knockdown. Furthermore, 
the expression levels of VLA-4 and CXCR4 were assessed by both qRT-PCR and flow cytometry and both adhesion to 
fibronectin-coated plates and migration toward CXCL12 were analyzed in Mec-1 cells treated with morin alone or in 
combination with fludarabine or ibrutinib.
Results: We observed that LMW-PTP is highly expressed in Mec-1 cells as well as in leukemic B lymphocytes puri-
fied from CLL patients compared to normal B lymphocytes. Morin treatment strongly decreased LMW-PTP expression 
levels in Mec-1 cells and potentiated the anticancer properties of both fludarabine and ibrutinib by increasing their 
apoptotic effects on leukemic cells. Moreover, morin negatively regulates adhesion and CXCL12-dependent migration 
of Mec-1 cells by affecting VLA-4 integrin expression and CXCR4 receptor recycling.
Conclusions: Morin treatment in CLL-derived Mec-1 cell line synergizes with conventional anticancer drugs currently 
used in CLL therapy by affecting leukemic cell viability and trafficking.
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Background
Low molecular weight protein tyrosine phosphatase 
(LMW-PTP) is an enzyme involved in cell proliferation 
control by dephosphorylating tyrosine kinase receptors 
and docking proteins involved in cell adhesion and regu-
lation of gene expression [1]. In the last decades, compel-
ling evidence suggested that LMW-PTP has an important 
role in modulating cancer cell responses such as apop-
tosis inhibition, cell motility and glucose metabolism. It 
is indeed overexpressed in different cancers, including 
colon cancer and neuroblastoma, and its expression is 
related to worse prognosis and reduced survival rate [2]. 
Similar results were obtained in a rat model of colorec-
tal cancer, where strongly increased LMW-PTP expres-
sion was already observable in pre-neoplastic lesions [3]. 
Interestingly, LMW-PTP also contributes to regulation of 
the glucose metabolism in different human cancer cells 
[4]. More recent studies demonstrated that LMW-PTP is 
involved in the regulation of apoptosis and in the acqui-
sition of drug resistance in many cancers [5]. Moreover, 
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high levels of LMW-PTP, usually associated with aggres-
sive cancer, induce resistance to chemotherapy. siRNA-
mediated knock-down of LMW-PTP strongly reduces 
the malignant potential of colon cancer cells [6, 7]. These 
data strongly suggest that targeting LMW-PTP phos-
phatase could be of potential interest to amplify the 
effects of the conventional therapies also in other types 
of cancer.
Chronic lymphocytic leukemia (CLL) is the most com-
mon B-cell neoplasm in Europe and United States, char-
acterized by progressive accumulation of monoclonal 
CD5+ B cells in peripheral blood, bone marrow, and 
peripheral lymphoid organs. CLL has a highly variable 
clinical course, ranging from a stable disease to a progres-
sive, severe and almost invariably fatal disease [8, 9], with 
subsequent strong implications for drug regimens, which 
are also highly variable. Together with the conventional 
drugs such as fludarabine, cyclophosphamide, chloram-
bucil and others [10], clinical trials have recently iden-
tified more specific inhibitors of B cell receptor (BCR) 
signaling such as ibrutinib, a Bruton tyrosine kinase (Btk) 
inhibitor [11, 12], idelalisib, a phosphoinositide 3-kinase 
(PI3K) inhibitor [13], and venetoclax, a Bcl-2 inhibitor 
[14], as effective alternatives to current chemoimmuno-
therapy-based regimens Because of the increasing side 
effects or resistance to drugs used for managing CLL, 
new natural compounds were recently tested for CLL 
treatment [15].
Morin, a bioactive flavonoid member of the family of 
Moraceae, has been reported to be endowed of pecu-
liar pharmacological properties [16]. Compelling evi-
dence demonstrated that morin is a bioactive compound, 
showing a broad range of pharmacological activities 
and very low cytotoxicity by modulating the activity of 
many enzymes. In some cases, morin shows a systemic 
protective action, reducing negative side effects of sev-
eral drugs, without interfering with their functions [17]. 
Moreover, we have recently demonstrated that morin 
reduces LMW-PTP protein levels and sensitizes mela-
noma cells to chemo- and radiotherapy [7]. In addition, 
we have also shown an in vivo action of Morin on colon 
carcinoma in a Pirc rats model system [18].
In this study we assessed the effect of morin on LMW-
PTP expression in the CLL-derived Mec-1 cell line, dem-
onstrating that morin potentiates the pro-apoptotic and 
anti-migratory effects of fludarabine and ibrutinib, two 
drugs currently used in CLL treatment.
Methods
Cells, antibodies and reagents
CLL-derived B-cell line Mec-1 were cultured in Roswell 
Park Memorial Institute (RPMI) with 7.5% bovine calf 
serum (BCS). Peripheral blood samples were collected 
from 9 patients satisfying standard morphologic and 
immunophenotypic criteria for CLL. B cells from 10 
buffy coats were used as healthy controls. At collection, 
patients had never received treatment. Primary B cells 
were purified by negative selection using RosetteSep 
B-cell enrichment Cocktail (StemCell Technologies, 
Vancouver, Canada) followed by density gradient cen-
trifugation on Lympholite (Cedarlane Laboratories, The 
Netherlands).
Rabbit polyclonal anti-LMW-PTP antibodies were pro-
duced in Raugei laboratory, anti-actin antibodies were 
from Santa Cruz Biotechnology Inc. (Heidelberg Ger-
many), anti-CXCR4 (C-X-C chemokine receptor type 
4) polyclonal antibodies were from Sigma-Aldrich (St. 
Louis, MO, USA), anti-CXCR4 monoclonal antibodies 
were from Abnova (Aachen, Germany), anti-CD49d-PE 
antibodies used for VLA-4 detection were from BD. Sec-
ondary peroxidase-labeled antibodies were from Santa 
Cruz Biotechnology. Human CXCL12 (C-X-C motif 
chemokine 12), fibronectin (FN), fludarabine and morin 
were purchased from Sigma-Aldrich; ibrutinib from Sell-
eckchem (Munich, Germany).
Immunoblotting
Cells were lysed on ice in 1× Laemli Buffer 
(0.5  mol/L Tris–HCl pH 6.8, 10% SDS, 20% glycerol, 
β-mercaptoethanol, 0.1% bromophenol blue), and sam-
ples were boiled for 10 min. Cell extracts were resolved 
by SDS-PAGE and transferred to PVDF membranes (Bio-
Rad Laboratories Segrate Milan, Italy). Membranes were 
incubated overnight at 4 °C with the appropriate primary 
antibody. After washing in TPBS-Tween-20 (0.1%), mem-
branes were incubated with the appropriate horseradish 
peroxidase-conjugated secondary antibodies (Santa Cruz 
Biotechnology) for 1  h. Proteins were detected using 
Clarity Western ECL (Bio-Rad) by Amersham 6000 (GE 
Healthcare).
Cell transfection
Mec-1 cells (1 × 105 cells/mL) were grown for 24 h and 
then transiently transfected with LMW-PTP siRNA 
(target sequence CCC ATA GTG CAC ACT TGT ATA), 
using the Hiperfect Transfection Reagent (Qiagen Italia, 
Milano, Italy) according to the manufacturer’s instruc-
tions. Briefly, the cells were transfected for 24  h with 
siRNA at a final concentration of 20 nmol/L. To test the 
specificity of LMW-PTP transfection, control cells were 
transfected with a scramble sequence (AllStars Negative 
Control siRNA; at a final concentration of 20  nmol/L; 
Qiagen) used as negative control. Immunoblotting 
assessed the efficiency of transfection.
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Apoptosis evaluation
Apoptosis was determined using Annexin-V-FLUOS 
Staining kit from Roche according to manufacturer’s 
instructions. 1 × 106  cells were washed in phosphate 
buffered saline (PBS), and centrifuged at 1300×g for 
5 min. Cell pellet was resuspended in 100 μL of Annexin-
V-FLUOS labeling solution and incubated for 10–15 min 
at room temperature in the dark. Five hundred microlit-
ers of incubation buffer were added and cells were ana-
lyzed by flow cytometry using a BDFACS Canto.
Analysis of receptor recycling, cell adhesion 
and chemotaxis
Flow cytometry was carried out using a Guava Easy 
Cyte (Millipore) cytometer. Analysis of CXCR4 was car-
ried out using fluorochrome-conjugated antibodies or 
isotype control used as negative control on cells fixed 
and permeabilized using the Cytofix/Cytoperm plus kit 
(BD). CXCR4 recycling following antibody-dependent 
downregulation was quantitated by flow cytometry as 
described [19]. Briefly, cells were incubated for 30  min 
on ice with CXCR4-specific antibodies, washed, shifted 
to 37  °C for 40  min, then subjected to acid stripping 
(time 0), and incubated for the indicated times at 37 °C. 
Receptor:antibodies complexes that had recycled to 
the cell surface were measured by labeling with fluoro-
chrome-conjugated secondary antibodies.
Adhesion assays on FN-coated plates in the presence 
or absence of 100  ng/mL CXCL12 were performed as 
previously described [20]. Briefly, 48-well plates were 
coated o/n at 4 °C with 10 mg/mL FN, washed with PBS 
and incubated for 30 min at 37 °C with RPMI 1% bovine 
serum albumin (BSA). Then, 2 × 105  cells/well serum-
starved Mec-1 cells were added. The plates were incu-
bated at 37  °C for 10  min, then added with 100  ng/mL 
CXCL12 for further 10 min. Cells that had not adhered 
(recovered in medium and washes) were resuspended in 
0.2  mL RPMI 7.5% BCS. Cells that remained adherent 
after 3 washes were recovered by 1-min incubation with 
trypsin/EDTA, immediately added with RPMI 7.5% BCS, 
washed and resuspended in 0.2  mL RPMI 7.5% BCS. 
Cells were counted by flow cytometry. The percentage 
of adherent cells was calculated as previously described 
[20]. Chemotaxis assays were carried out using 24-well 
transwell chambers with 5-µm pore polycarbonate mem-
branes (Corning Life Sciences, Schiphol-Rijk, The Neth-
erlands) as described [21]. Briefly, filters were soaked 
overnight in chemotaxis medium (RPMI 1% BSA). 
500 µL of chemotaxis medium with or without 100 nM 
CXCL12 was placed in the lower chamber, and 100  µL 
of the cell suspension (5 × 105  cells/sample) in chemot-
axis medium was placed in the upper chamber. Samples 
without chemokine were used as negative controls. After 
3 h of incubation at 37 °C in humidified air with 5%  CO2, 
the upper chamber was emptied, filters were removed, 
and the cells in the lower chamber were counted by 
flow cytometry. The migration index was calculated by 
determining the ratio of migrated cells in treated versus 
untreated samples.
RNA purification and real‑time PCR
Total RNA was extracted from Mec-1 cells and retrotran-
scribed as previously described [22]. Two independent 
reverse transcription reactions were performed on each 
RNA sample. Quantitative real-time polymerase chain 
reaction (qRT-PCR) was performed in triplicate on each 
cDNA on 96-well optical PCR plates (Sarstedt) using 
SSo Fast EvaGreenR SuperMix (Bio-Rad) according to 
the manufacturer’s instructions and a CFX96 Real-Time 
system (Bio-Rad). After an initial denaturation for 3 min 
at 95  °C, denaturation in the subsequent 42 cycles was 
performed for 10  s at 95  °C, followed by 30  s of primer 
annealing at 60 °C. Results were processed and analyzed 
using CFX Manager Version 1.5 software (Bio-Rad). 
Transcript levels were normalized to HPRT1, used as a 
housekeeping gene. Primers used for amplification are 
listed in Additional file 1: Table S1.
Statistical analysis
All statistical analyses were performed with Micro-
cal Origin 8, using Student t test; data, reported as the 
mean ± SD, were considered significant if p values ≤ 0.05.
Results
Morin strongly reduces LMW‑PTP expression levels 
in Mec‑1 cells
LMW-PTP is overexpressed in several solid cancer types 
and its expression is related to tumour onset and pro-
gression [2, 23], but little is known about the LMW-PTP 
expression levels in human B cells [24]. We quantitated 
by immunoblot the expression levels of LMW-PTP in a 
variety of human B cell lines and we observed that LMW-
PTP was expressed at high levels in some of them includ-
ing the CLL-derived Mec-1 cell line (Additional file  1: 
Figure  S1). Moreover, we assessed LMW-PTP protein 
levels in purified B lymphocytes from peripheral blood of 
healthy controls (HC) or CLL patients (B-CLL), in com-
parison with Mec-1 cells. As shown in Fig. 1a, LMW-PTP 
expression was strongly increased in CLL B cells com-
pared with normal B cells, as well as in the CLL-derived 
cell line Mec-1, suggesting a relevant role for this phos-
phatase in CLL pathogenesis (**p ≤ 0.01). Interestingly, 
24 h treatment of Mec-1 cells with 50 μM morin resulted 
in a strong decrease in LMW-PTP expression (Fig.  1b) 
compared to untreated control, that could be relevant for 
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CLL disease progression and treatment (**p ≤ 0.01). The 
negative effect of morin on LMW-PTP protein expres-
sion is not specific for Mec-1 cells. It was indeed also 
observed in the lymphoblastoid cell line EBV-B (Addi-
tional file 1: Figure S2), which expresses LMW-PTP levels 
comparable to Mec-1 cells (Additional file 1: Figure S1).
Morin treatment ameliorates conventional drug‑induced 
apoptosis in Mec‑1 leukemic cells by targeting LMW‑PTP 
expression
Previous reports demonstrated that high levels of LMW-
PTP were usually associated to aggressive cancer and 
induced resistance to chemotherapy, effects that could be 
strongly counteracted by LMW-PTP silencing [6, 7]. We 
first assessed the effectiveness of siRNA-mediated LMW-
PTP knock-down (Additional file 1: Figure S3). We then 
assessed the effects of LMW-PTP silencing on Mec-1 
cell viability, alone or in combination with fludarabine 
or ibrutinib, by Annexin V staining. As shown in Fig. 2, 
LMW-PTP silencing alone was able to strongly induce 
apoptosis of Mec-1 cells compared to untreated cells 
(nt) used as negative control, more than that observed 
when cells were treated with fludarabine (Fig.  2a) or 
ibrutinib (Fig.  2b) alone. Interestingly, the combination 
of fludarabine or ibrutinib treatment with LMW-PTP 
silencing induced significative higher levels of cell death 
(***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05). These data demon-
strated that LMW-PTP silencing increases cell death 
alone and in combination with conventional drugs in 
Mec-1 cells.
Because of the fact that morin is known to induce apop-
tosis in different types of cancer cells [17, 25] and that 
morin treatment was able to downregulate the expression 
levels of LMW-PTP in Mec-1 cells (Fig. 1b), we tested the 
effect of morin alone or in combination with fludarabine 
or ibrutinib on Mec-1 cell viability. Morin alone did not 
enhance apoptosis of Mec-1 cells beyond the low basal 
levels, compared to “dmso” sample used as negative con-
trol (Fig.  3a, b). Interestingly, treatment of Mec-1 cells 
with 50 µM morin in combination with increasing con-
centrations of fludarabine (ranging from 0.35 to 35 µM, 
see Fig. 3a) or ibrutinib (ranging from 0.1 to 10 µM, see 
Fig. 3b) induced a significant increase in cell death com-
pared to fludarabine or ibrutinib alone (***p ≤ 0.001, 
**p ≤ 0.01). Similar results were obtained treating Mec-1 
cells with suboptimal concentrations of fludarabine 
(3.5  µM) or ibrutinib (0.1  µM) and increasing the con-
centration of morin, ranging from 0.5 µM to 10 µM (see 
Fig. 3c, d).
Taken together these data demonstrate that morin, by 
reducing the LMW-PTP expression, enhances the sensi-
tivity of Mec-1 cells to pro-apoptotic drugs.
Morin amplifies the inhibitory effects of conventional 
drugs on B-cell adhesion and migration.
The stromal microenvironment has emerged as key 
player in CLL pathogenesis [26], exerting the double 
function of creating a proliferative niche for leukemic 
Fig. 1 LMW-PTP phosphatase expression is downregulated by morin treatment in Mec-1 cells. a Left: Immunoblot analysis with anti-LMW-PTP 
antibodies from lysates of Mec-1 cells and primary B cells purified from peripheral blood of a representative healthy control (HC) or CLL patient 
(B-CLL). The stripped filters were reprobed with anti-actin antibodies as loading control. Right: quantification by laser densitometry of the protein 
bands. Each sample was normalized to the relative actin and data are expressed as percentage (value of Mec-1 cells set as 100). The quantification 
of protein levels in Mec-1 cells are relative to three independent experiments. For primary B cells the number of samples is HC n = 5 and B-CLL 
n = 9. Data are expressed as mean ± SD. b Quantification by laser densitometry of the LMW-PTP protein levels normalized to the respective actin 
in Mec-1 cells treated with 50 μM morin or DMSO as control for 24 h. A representative immunoblot analysis is shown on the top of the panel. The 
quantifications are relative to three independent experiments (n = 3). Error bars, SD. **p ≤ 0.01
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cells and protecting them from the action of conventional 
chemotherapeutic drugs. Homing to lymphoid organs is 
strongly potentiated in CLL B cells, thereby prolonging 
leukemic cell residency into these protective niches [27]. 
Integrins and chemokine receptors are both implicated 
in B-cell homing, by regulating adhesion to endothelial 
cells and transendothelial migration, respectively [28, 29]. 
B-cell adhesion is mainly regulated by the integrin Very 
Fig. 2 LMW-PTP knockdown results in enhanced Mec-1 cell apoptosis. a, b Flow cytometric analysis of the percentages of Annexin  V+/PI− in Mec-1 
cell silenced (siRNA) or not for LMW-PTP, treated with either DMSO or 3.5 µM fludarabine (a) or 0.1 µM ibrutinib (b) for 24 h. Data are expressed as 
the mean values ± SD determined from three independent experiments. ***p ≤ 0.001, **p ≤ 0.01
Fig. 3 Morin treatment enhances fludarabine- or ibrutinib-induced apoptosis in Mec-1 cells. a, b Flow cytometric analysis of the percentages of 
Annexin  V+/PI− in Mec-1 cell samples treated with either DMSO or 50 µM morin, in the absence or presence of fludarabine (ranging from 0.35 
to 35 µM, a) or ibrutinib (ranging from 0.1 to 10 µM, b) for 24 h. c, d Flow cytometric analysis of the percentages of Annexin  V+/PI− in Mec-1 cell 
samples treated with either DMSO or 3.5 µM fludarabine (c) or 0.1 µM ibrutinib (d), in the absence or presence of morin (ranging from 0.5 to 10 µM). 
Data reported in the histogram on the right represent the mean values ± SD determined from three independent experiments. ***p ≤ 0.001, 
**p ≤ 0.01, *p ≤ 0.05
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Late Antigen-4 (VLA-4), which interacts with its ligands 
vascular cell adhesion molecule 1 (VCAM-1) and FN.
The effect of morin on leukemic cell adhesion was 
addressed treating Mec-1 cells with 0.1 μM ibrutinib or 
3.5 μM fludarabine for 16 h and then adding or not 50 μM 
morin for 6 h at 37 °C. Cells were subsequently plated on 
immobilized FN in the presence or absence of CXCL12 
and the proportion of cells that had adhered after a short 
incubation was determined by flow cytometry. Morin 
treatment alone negatively regulated CXCR4-dependent 
adhesion to FN compared to the untreated sample (nt) 
used as negative control, with an effect comparable to 
the treatment with the conventional drugs fludarabine 
and ibrutinib (Fig.  4a). Interestingly the combination 
of morin with either fludarabine or ibrutinib was more 
effective at inhibiting the ability of Mec-1 cells to adhere 
to FN compared with single agent treatments. Consistent 
with this finding, real time and cytofluorometric analy-
sis for VLA-4 expression revealed a strong reduction of 
transcript and protein levels in Mec-1 cells treated with 
0.1 μM ibrutinib or 3.5 μM fludarabine or 50 μM morin 
or the combination of morin with either fludarabine or 
ibrutinib for 24  h (Fig.  4b, c). Statistical significance is 
indicated (***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05).
The effect of morin treatment on B-cell chemotaxis 
was addressed in transwell migration assays, using 
CXCL12 as chemoattractants. CXCR4-dependent 
migration was impaired in morin treated Mec-1 cells 
compared with untreated cells used as negative control, 
as well as in Mec-1 cells treated with 0.1 μM ibrutinib or 
3.5 μM fludarabine as single agents (Fig. 5a). The migra-
tory potential was further inhibited when cells were 
treated with the combination of morin and fludarabine 
or ibrutinib (Fig.  5a). qRT-PCR and cytofluorometric 
analysis of CXCR4 expression in Mec-1 cells did not 
reveal any significant modulation in the transcript or 
protein levels following morin treatment alone or in 
combination with fludarabine or ibrutinib (Fig.  5b, c). 
The relative gene transcript abundance was determined 
using the ddCt method, relative to the untreated sam-
ple (nt). Statistical significance is indicated for panel a 
and d (***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05).
CXCR4 expression at the plasma membrane is 
dynamically regulated by its downmodulation in the 
presence of high ligand concentrations and its recycling 
when these decrease [30], and it was previously dem-
onstrated that enhanced receptor recycling contributes 
to the increased surface CXCR4 levels on CLL cells and 
enhanced migratory responses [31]. Interestingly, here 
we showed that morin treatment strongly inhibited 
CXCR4 receptor recycling in Mec-1 cells, both as single 
agent or in combination with fludarabine or ibrutinib 
(Fig. 5d), accounting for the inhibitory effect observed 
on CXCR4-dependent migration (Fig.  5a). Hence, 
morin acts, alone or in combination with fludarabine 
or ibrutinib, as a negative regulator of both cell adhe-
sion and CXCR4-dependent migration in Mec-1 cells 
by affecting VLA-4 expression levels and inhibiting 
CXCR4 receptor recycling, respectively.
Fig. 4 Morin treatment in combination with conventional drugs impairs CXCR4-dependent adhesion and VLA-4 expression in Mec-1 cells. a 
Quantification by flow cytometry of the percentage of Mec-1 cells untreated or treated with 0.1 μM ibrutinib or 3.5 μM fludarabine or 50 μM morin 
or the combination of morin with either fludarabine or ibrutinib for 24 h, that adhered to 48-well plates coated with 10 μg/mL fibronectin following 
a 10 min ìtreatment with 100 ng/mL CXCL12. The data, which refer to quadruplicate samples from three independent experiments, are presented as 
fold of adherent cells in CXCL12 stimulated samples versus the corresponding unstimulated controls. b Quantitative RT-PCR analysis of VLA-4 mRNA 
on Mec-1 cells treated as in panel A. The relative gene transcript abundance was determined on triplicate samples using the ddCt method (n = 3). c 
Flow cytometric analysis of VLA-4 on Mec-1 cells treated as in panel A and permeabilized (n = 3). Error bars, SD; ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05
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Discussion
LMW-PTP is overexpressed in different cancer types 
and its expression is related to a worse prognosis and 
reduced survival rate [2]. Chiarugi et al. [23] showed that 
LMW-PTP increases engrafted tumor growth in nude 
mice, confirming a possible role of this enzyme in tumo-
rigenesis also in in  vivo models. Moreover independent 
studies demonstrated that over-expression of LMW-PTP 
confers resistance to vincristine in leukemic cells [5] and 
enhances the malignant potential of colorectal cancer 
cells, inducing drug resistance and modulating cell motil-
ity [6].
Here we demonstrated that LMW-PTP phosphatase is 
expressed at high levels in the CLL-derived Mec-1 B cell 
line and is overexpressed in primary B cells purified from 
peripheral blood of CLL cells compared with healthy 
controls (Fig. 1a).
Because of CLL is primarily a disease of defective 
apoptosis rather than uncontrolled proliferation [4, 8, 
32], introducing in the treatment of this disease agents 
able to induce leukemic cell death it is one of the main 
goal that have to be achieved. Here we use the flavo-
noid morin that was largely demonstrated to be able 
to sensitize cancer cells to apoptosis, downregulat-
ing expression of the main anti-apoptotic proteins and 
modulating the expression of many enzymes. We found 
that morin is able to downregulate LMW-PTP levels 
in Mec-1 cells (Fig. 1b) and that treatment with morin 
Fig. 5 Morin treatment in combination with conventional drugs inhibit CXCR4-dependent migration and CXCR4 receptor recycling in Mec-1 cells. 
a Migration of Mec-1 cells treated as in Fig. 4, stimulated or not for 3 h with 100 ng/mL CXCL12. The data, obtained on duplicate samples from at 
least three independent experiments, are presented as mean migration index ± SD (ratio of migrated cells in chemokine-treated versus untreated 
samples). b Quantitative RT-PCR analysis of CXCR4 mRNA on Mec-1 cells treated as in Fig. 4. The relative gene transcript abundance was determined 
on triplicate samples using the ddCt method (n = 3). c Flow cytometric analysis of CXCR4 on Mec-1 cells treated as in Fig. 4 and permeabilized 
(n = 3). d Flow cytometric analysis of CXCR4 recycling in Mec-1 cells treated as in Fig. 4. Data are presented as  % of internalized receptors that have 
recycled to the cell surface and refer to duplicate samples (n = 3). Error bars, SD; ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05
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is able to increase Mec-1 cell sensitivity to apoptosis 
induced by fludarabine or ibrutinib, two drugs cur-
rently used in CLL treatment (Fig.  3). The mechanism 
by which morin contributes to apoptosis induction 
appears to be related to its ability to reduce LMW-PTP 
levels, since LMW-PTP knock down itself results in 
enhanced leukemic cell death (Fig. 2).
The stromal microenvironment has emerged as a key 
player in CLL cell survival and expansion [32–34]. B 
lymphocyte homing to SLOs and BM is regulated by a 
balance between homing receptors, such as CXCR4 and 
CCR7 [35, 36], and receptors that promote lymphocyte 
egress from their homing sites, such as sphingosine-
1-phosphate receptor 1 (S1PR1) [37]. CLL cells display 
an altered balance in the surface expression of these 
receptors toward the homing ones [31, 38, 39], result-
ing in the prolonged residency of leukemic cell in the 
pro-survival stromal niche of SLOs where they are sub-
jected to survival signal and protected from chemo-
therapy [40]. Hence, searching for compounds that are 
able to restore normal lymphocyte trafficking by inhib-
iting the enhanced adhesion and migration observed 
in leukemic cells remains one of the principal tasks in 
CLL treatment. Ibrutinib alone was previously demon-
strated to have a role in CLL cell trafficking by regulat-
ing the expression levels of homing receptors [39] and 
in the regulation of CXCR4 receptor recycling [26]. 
Here we observed that morin was able to synergize 
with fludarabine and ibrutinib in decreasing the ability 
of Mec-1 cells to adhere to FN (Fig. 4a) and to migrate 
toward a CXCL12 gradient (Fig.  5a), by regulating 
respectively VLA-4 integrin expression levels (Fig.  4b) 
and CXCR4 recycling (Fig. 5d).
Further experiments are required to assess whether 
LMW-PTP over-expression correlates with a faster dis-
ease progression and/or resistance to pharmacological 
treatments, and if it may be predictive for the overall sur-
vival. In addition, in order to explore the potential exploi-
tation of Morin as adjuvant therapy to small molecule 
drugs and/or biologicals currently used for CLL treat-
ment, it will be mandatory to carry out in  vivo experi-
ments using appropriate animal models of CLL, such as 
the Eμ-TCL1 mouse [41, 42].
Conclusions
These data provide a rationale for using morin as sensi-
tizing agent to improve the effectiveness of traditional 
therapies by inducing apoptosis of leukemic cells and 
by modulating their ability to recirculate from SLOs to 
peripheral blood where they are more susceptible to con-
ventional anticancer drugs.
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antibodies as loading control. Right. Quantification by laser densitometry 
of the protein bands. Each sample was normalized to the respective actin 
and data are expressed as percentage (value of Mec-1 cells set as 100). 
Data are expressed as mean ± SD. Figure S2. Quantification by laser 
densitometry of the LMW-PTP protein levels normalized to the respective 
actin in EBV-B cells treated with 50 μM morin or DMSO as control for 24 h. 
A representative immunoblot analysis is shown on the top of the panel. 
The quantifications are relative to three independent experiments. Error 
bars, SD. ***p ≤ 0.001. Figure S3. Quantification by laser densitometry of 
the LMW-PTP protein levels normalized to the respective actin in Mec-1 
cells transfected with LMW-PTP siRNA or scramble. A representative 
immunoblot analysis is shown on the top of the panel. The quantification 
are relative to three independent experiments. Error bars, SD. ***p ≤ 0.001.
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